|1.||Laguna, P: 5 articles (09/2013 - 01/2005)|
|2.||Lissitchkov, T: 4 articles (09/2013 - 11/2009)|
|3.||Antonov, A: 4 articles (09/2013 - 11/2009)|
|4.||Gercheva, L: 4 articles (09/2013 - 11/2009)|
|5.||Matysiak, M: 4 articles (09/2013 - 11/2009)|
|6.||Levy, Jerrold H: 3 articles (04/2015 - 11/2008)|
|7.||Tjønnfjord, G E: 3 articles (03/2015 - 03/2004)|
|8.||van Ryn, Joanne: 3 articles (06/2014 - 06/2010)|
|9.||Aznar, J A: 3 articles (09/2013 - 11/2009)|
|10.||Klukowska, A: 3 articles (03/2012 - 01/2005)|
03/01/2010 - "activated prothrombin complex concentrates and recombinant activated FVII) have proven effective in the treatment of bleeding episodes, but as there are insufficient data to determine the optimal approach to immune tolerance induction in this group of patients, their optimal management remains controversial. "
03/01/1998 - "In this review we discuss recent evidence suggesting prothrombin complex concentrates lead to faster, and more complete, correction of coagulation and, in the context of intracranial bleeding, may be associated with improved neurological status. "
10/01/2002 - "Activated prothrombin complex concentrates (APCCs) are effective in the therapy of bleeding episodes in hemophilic patients with inhibitors. "
09/07/1987 - "Although prothrombin-complex concentrates were effective in the control of the majority of minor bleeding episodes, they were effective in only 50% of severe episodes of bleeding and did not prevent the early development of haemophilic arthropathy."
10/01/2004 - "Emerging data suggest that prophylaxis using activated prothrombin complex concentrates may be effective and safe in reducing the incidence of joint bleeding during immune tolerance therapy and for patients in whom immune tolerance induction fails. "
|2.||Hemophilia A (Haemophilia)
03/01/1999 - "Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery."
09/01/1983 - "Studies of factor IX concentrate therapy in hemophilia."
03/01/2015 - "In a prospective crossover study haemophilia A patients with high titre inhibitors were included to receive a dose of 75 U kg(-1) activated prothrombin complex concentrates (aPCC) intravenously. "
01/01/2014 - "Some hemophilia A patients who have developed inhibitors are poorly responsive to activated prothrombin complex concentrates (aPCC) after daily dosage, but the mechanism(s) underlying this remain unknown. "
09/01/2010 - "Retrospective data were collected from 15 haemophilia A patients with FVIII inhibitors who had been treated with Octaplex. "
|3.||Hemophilia B (Haemophilia B)
03/01/1999 - "Thus, continuous infusion with this highly purified factor IX concentrate with improved viral safety is effective for surgery in haemophilia B."
05/01/2008 - "OCTANINE F is a high-purity blood clotting factor IX concentrate that has been shown to be effective and safe in adults with haemophilia B. "
01/01/1996 - "The safety and efficacy of a monoclonal antibody purified factor IX concentrate were evaluated in two continuing trials of 32 previously untreated patients with mild, moderate, or severe hemophilia B. "
01/01/1996 - "Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B."
07/01/2011 - "A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B."
09/01/2014 - "Studies in animals or healthy volunteers showed a correction of the biological parameters using prothrombin complex concentrates activated or not, without reducing the volume of hematoma. "
06/01/2006 - "The aim of the present study was to compare the acute treatment strategies of OAT-associated ICH using vitamin K (VAK), fresh frozen plasma (FFP), and prothrombin complex concentrates (PCCs) with regard to hematoma growth and outcome. "
06/01/2006 - "Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates."
01/01/2012 - "Recombinant activated coagulation factor VII and prothrombin complex concentrates are equally effective in reducing hematoma volume in experimental warfarin-associated intracerebral hemorrhage."
04/01/1996 - "The effect of non-activated prothrombin complex concentrate (Proplex ST) on intraperitoneal hematoma in a hemophilia A patient with a factor VIII inhibitor."
|5.||Intracranial Hemorrhages (Intracranial Hemorrhage)
06/01/2010 - "Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature."
12/01/2014 - "Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage."
12/01/2014 - "There are no studies demonstrating that prothrombin complex concentrates (PCC) improves outcome compared FFP in patients with warfarin-associated intracranial hemorrhage. "
10/01/2014 - "Response to letter to the editor: prothrombin complex concentrates in warfarin-associated intracranial hemorrhage."
10/01/2014 - "Comments on the outcomes of prothrombin complex concentrates in warfarin-associated intracranial hemorrhage."
|1.||Factor VIII (Coagulation Factor VIII)
|2.||recombinant FVIIa (rFVIIa)
|3.||Factor VIIa (Activated Factor VII)
|4.||Factor IX (PTC)
|7.||Factor VII (Proconvertin)
|8.||Prothrombin (Factor II)
|10.||Factor X (Stuart Factor)
|1.||Length of Stay
|2.||Renal Dialysis (Hemodialysis)